Barington Lights a Fuse at Bath & Body Works — the Stock at 5x EBITDA Is the Real Headline

Barington Capital disclosed to Bloomberg on September 10 that it has built a roughly one million-share position in Bath & Body Works — about 0.5% of the 201.6 million shares outstanding, per the company's most recent filing. That is a tiny stake in absolute terms, and far smaller than the position Barington took in Victoria's Secret in mid-2025, but the firm is not a passive shareholder. CEO James Mitarotonda told Bloomberg the company should draw \"considerable interest\" from private-equity buyers; Barington plans to send a formal letter to the BBWI board in the coming weeks and is evaluating a proxy contest for board representation.

The pattern is familiar. In December 2024 Barington pushed Macy's to cut costs and explore selling its real estate. In December 2025 it joined Elliott and Starboard in pressing Bill Holdings to consider a sale. Its Victoria's Secret campaign from June 2025 — which called for a board overhaul and the end of the company's poison pill — has dragged on for fifteen months without a sale, but also without a buyback program to placate shareholders. BBWI's official response was boilerplate: the company \"regularly engages with shareholders and evaluates opportunities to enhance shareholder value.\" The market read it differently — shares rose as much as 3.3% in after-hours trading on the Bloomberg report.

The reason a 0.5% stake can move the stock is that the underlying business is mispriced on a scale rare in U.S. retail. Bath & Body Works closed the September 10 session with a market capitalization of about $3.6 billion against roughly $1.4 billion of trailing-twelve-month EBITDA — an EV/EBITDA multiple of 5.3x, the lowest since the company spun out of L Brands in 2021. The five-year history tells the story starkly: market cap fell from $14.7 billion in FY2021 to $4.6 billion in FY2025 and now $3.6 billion, while EBITDA stayed in a $1.4–1.6 billion band. The stock is doing the opposite of what a turnaround story should.

The market is paying for the deterioration BBWI itself is forecasting. The company now guides fiscal 2026 net sales down 2.5% to 4.0% versus $7.29 billion in fiscal 2025, with adjusted EPS of $2.60–$2.80 versus $3.21 last year. The Q3 guide is the more painful datapoint: adjusted EPS of just $0.07–$0.12 against a year-ago quarter of $0.49. Bears argue a brand in slow, secular decline cannot command a healthy multiple even after the 76% drawdown. The bull case — the one Barington is implicitly making — is that a brand generating $650 million of free cash flow on a $3.6 billion equity is not in slow decline, it is in single-digit-percent temporary compression. The 28.9% trailing free-cash-flow yield says the market is treating BBWI like a melting ice cube.

Take-private math is what Barington is selling, and it works. Bath & Body Works generated roughly $851 million of free cash flow in fiscal 2025 and is guiding to ~$650 million for fiscal 2026, which is depressed only because of working-capital normalization. At the current $3.57 billion equity value, even the depressed FY2026 number implies an 18% FCF yield. Adding back the $3.9 billion of net debt, enterprise value is ~$7.5 billion — 5.5x trailing EBITDA. A private-equity consortium writing a 30% control premium to the current equity would still pay only 7.0x trailing EBITDA, a number routinely cleared in 2026 retail deals (median 13.4x per CohnReznick's H1 2026 private-equity report).

Three things make the LBO more attractive than the public-market valuation suggests. First, BBWI's digital business just returned to growth for the first time since 2021, and the Amazon partnership launched in February 2026 has tripled sales in that channel by Q2, per management commentary. Second, the company is closing Ulta Beauty distribution starting July 2026 — a new lane that monetizes the brand without capex-heavy store builds. Third, capital allocation is under shareholder pressure: management's fiscal 2026 plan explicitly assumes zero share repurchases while redeeming $284 million of January 2027 bonds. Barington's \"buy back stock\" demand is, in effect, an instruction to stop de-prioritizing the equity — which is what a credible sale threat does to a board.

The bigger story is not Bath & Body Works specifically — it is the size of the valuation gap that has opened between two sub-segments of specialty retail. Companies growing revenue and digital share trade at 13–18x trailing EBITDA: Ulta Beauty at 13.2x, Tapestry at 12.4x, Williams-Sonoma at 14.0x, Ross Stores at 17.7x. Companies whose narratives have stalled — even when cash flow is intact — trade at half those multiples: BBWI at 5.3x and Macy's at 5.5x are the deepest discouts, but Victoria's Secret at 12.6x is still meaningfully below the cohort given a recent turnaround and a renamed ticker (VSXY, since June 2026).

Barington's argument — laid out for Macy's in late 2024 and now for BBWI — is that a PE buyer can buy the whole enterprise at 6–7x EBITDA, lever it to 4–5x, and earn a 20%+ IRR just by maintaining the existing cash-flow profile. That math is harder at Ulta Beauty or Williams-Sonoma multiples, which is precisely why activists are targeting the bottom of the table. Insider buying reinforces the value case: BBWI director Francis Hondal bought 50,128 shares at $15.00 on November 21, 2025, and a second director bought 10,000 shares at $15.58 the following week — well before the Barington news, in both cases at prices implying a sub-6x EV/EBITDA. The board is not arguing against the thesis with its own wallet.

The asymmetric setup is the reason this matters beyond BBWI. The Q3 FY2026 guide and the Q4 trajectory will tell investors whether the valuation discount is justified or stranded. A board that ignores a credible activist with a credible math is asking for a proxy fight; a board that engages buys itself a chance to dictate the timeline of any sale. Either outcome rewards shareholders — but the larger share of the reward sits with whoever holds the equity into a strategic-review announcement, not whoever waits for a print. The market is finally pricing that path, and Barington's role was not to create it but to point at it.